Effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimer's disease

George T. Grossberg, Frederick A. Schmitt, Meng Xiangyi Meng, Sibel Tekin, Jason Olin

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Alzheimer's disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind, placebo- and active-controlled, 24-week clinical trial, the specific effects of rivastigmine patch on individual ADAS-cog items and cognitive domains (memory, language, and praxis) were explored. The mean baseline to week 24 changes were calculated for each ADAS-cog item and domain in this exploratory, hypothesis-generating analysis. Patients on 9.5 mg/24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch, and 3 to 12 mg/d rivastigmine capsules showed improvements over placebo on the memory and praxis ADAS-cog subscales. The rivastigmine patch groups also showed improvements on the language subscale. Significant differences versus placebo were seen on several individual item scores in the rivastigmine-treated groups. Rivastigmine patch was associated with improvements on the memory, praxis, and language domains of cognition in patients with mild-to-moderate AD.

Original languageEnglish
Pages (from-to)627-633
Number of pages7
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Issue number8
StatePublished - Dec 2010

Bibliographical note

Copyright 2018 Elsevier B.V., All rights reserved.


  • Alzheimer's disease
  • cognition
  • rivastigmine
  • transdermal patch

ASJC Scopus subject areas

  • Neuroscience (all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimer's disease'. Together they form a unique fingerprint.

Cite this